


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/574,922
		Filing Date	10/12/2004
Date Submitted: <u>March 5, 2007</u> (use as many sheets as necessary)		First Named Inventor	Ralph Patrick BRAUN
		Art Unit	1633
Sheet 1 of 1		Examiner Name	Unassigned
		Attorney Docket Number	036481-0176



U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	B1	2005-0143284 A1	06/30/2005	THOMSEN	
	B2	2005-0256070 A1	11/17/2005	BRAUN	
	B3	2005-0266024 A1	12/01/2005	BRAUN	
	B4	2006-0088542 A1	04/27/2006	BRAUN	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	B5	CA 2 383 496 A1	01/18/2001	DELCAYRE		
	B6	RU 2 174 845 C2	02/10/1998			
	B7	WO 94/16727	08/04/1994	ALKEMADE et al.		
	B8	WO 99/67285	12/29/1999	DEPLA et al.		
	B9	WO 01/04140	01/18/2001	DELCAYRE		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B10	KILPATRICK et al., "Rapid Development of Affinity Matured Monoclonal Antibodies Using RIMMS," <u>Hybridoma</u> , vol. 16, no. 4, Mary Ann Liebert, Inc., 1997, pp 381-389	
	B11	KILPATRICK et al., "Gene Gun Delivered DNA-Based Immunizations Mediate Rapid Production of Murine Monoclonal Antibodies to the Flt-3 Receptor," <u>Hybridoma</u> , vol. 17, no. 6, Mary Ann Liebert, Inc., 1998, pp 569-576	
	B12	OLSEN et al., "Immunogenicity and Efficacy of Baculovirus-Expressed and DNA-Based Equine Influenza Virus Hemagglutinin Vaccines in Mice," <u>Vaccine</u> , vol. 15, no. 10, Elsevier Science Ltd., 1997, pp 1149-1156	
	B13	PERTMER et al., "Gene Gun-Based Nucleic Acid Immunization: Elicitation of Humoral and Cytotoxic T Lymphocyte Responses Following Epidermal Delivery of Nanogram Quantities of DNA," <u>Vaccine</u> , vol. 13, no. 15, Elsevier Science Ltd., 1995, pp 1427-1430	
	B14	PRAYAGA et al., "Manipulation of HIV-1 gp120-specific Immune Responses Elicited Via Gene Gun-Based DNA Immunization," <u>Vaccine</u> , vol. 15, no. 12/13, Elsevier Science Ltd., 1997, pp 1349-1352	

Examiner Signature	/Q. Janice Li/ (04/30/2008)	Date Considered	
--------------------	-----------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.